Press Releases September 4, 2026 09:15 AM

Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference

Integra LifeSciences Announces Participation in Two Major 2026 Healthcare Conferences

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
IART

Integra LifeSciences Holdings Corporation will present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference, showcasing its leadership team and company vision to investors and industry professionals. Live webcasts of the presentations will be available on the company's investor relations website.

Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference
IART
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Integra's CFO and Chief Commercial Officer will present at the Wells Fargo Healthcare Conference on September 9, 2026.
  • The CEO will present at the Morgan Stanley Healthcare Conference on September 15, 2026.
  • The presentations will be webcast live, offering transparency and direct engagement with investors.

PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Lea Knight, chief financial officer, and Michael McBreen, chief commercial officer, will present at the 2026 Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 2:15 p.m. ET. Stuart Essig, chairman and chief executive officer, will present at the 2026 Morgan Stanley Healthcare Conference on Tuesday, September 15, 2026, at 4:05 p.m. ET.

A live webcast of the presentations will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS.

About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. For our latest news and information, visit www.integralife.com.

Investor Relations:
Chris Ward
(609) 772-7736
[email protected]   

Media Contact:
Laurene Isip
(609) 208-8121
[email protected] 


Integra LifeSciences Holdings Corporation


Risks

  • Market volatility around conference presentations could influence investor sentiment.
  • No new product announcements or financial guidance provided in this press release, limiting impact on stock movement.
  • Competitive landscape in medical technology and healthcare can affect expectations despite conference participation.

More from Press Releases

UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights Nov 4, 2026 BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Nov 4, 2026 Jasper Therapeutics Announces 1-for-30 Reverse Stock Split Nov 4, 2026 Twin Disc Announces First Quarter Results Nov 4, 2026 UniFirst Declares Increased Cash Dividends Oct 30, 2026